Several new agents to modulate iron metabolism, such as anti-hepcidin antibody (LY2787106) (262), anti-ferroportin antibody (LY2928057) (263), and anti-matriptase-2 antibody (RAP-536L and RLYB331), have been investigated (264), and are all beneficial in the treatment of anemia; hence, drug combinations incorporating these agents represent a potential superior option. The gene discussed is SLC40A1; the disease is anemia.